Abstract

Bosentan 6.25-mg/mL Oral Suspension

Author(s): Allen Loyd V Jr

Issue: Nov/Dec 2016 - Volume 20, Number 6

Page(s): 505

Download in electronic PDF format for $75
  • Bosentan 6.25-mg/mL Oral Suspension Page 1

Abstract

A formulation for preparing Bosentan 6.25-mg/mL Oral Suspension. Includes ingredients, method of preparation, discussion, and references for the compounding pharmacist.

Related Keywords

  • formulation
  • hazardous medication
  • pulmonary arterial hypertension
  • bosentan
  • exercise capacity

Related Categories

  • FORMULATIONS
  • CARDIOLOGY
  • RESPIRATION/LUNG/BREATHING
  • HAZARDOUS DRUGS

Printer-Friendly Version

Related Articles from IJPC

Issue/Page
View/Buy		 Title/Author
(Click for Abstract / Details / Purchase)
Nov/Dec 2016
Pg. 505
Bosentan 6.25-mg/mL Oral Suspension
Author(s): Allen Loyd V Jr
Mar/Apr 2003
Pg. 106-113
Veterinary Transdermal Medications: A to Z
Author(s): Davidson Gigi S
May/Jun 2004
Pg. 181-185
Compounding in the Pharmacy Curriculum: Beyond the Basics
Author(s): Hinkle Amanda R, Newton Gail D
Nov/Dec 2004
Pg. 462-465
Basics of Compounding for Cough
Author(s): Allen Loyd V Jr
Jan/Feb 2013
Pg. 24-27
Treatment of Canine Pulmonary Hypertension: Is Tadalafil an Appropriate Alternative to Sildenafil?
Author(s): Wung Deanna
Jan/Feb 2010
Pg. 40-45
Diverse Challenges in Pediatric Compounding: Treating Pulmonary Hypertension, Uncombable Hair Syndrome, and Acanthamoeba keratitis
Author(s): Muller George, Young Thomas W, Reina Rachel, Caldwell Delmar R
Nov/Dec 2006
Pg. 405-408
Application of Sildenafil for Pulmonary Hypertension in Canines and Foals
Author(s): Davidson Gigi S
Mar/Apr 2016
Pg. 145
Carvedilol 3.125-mg, 6.25-mg, 12.5 mg, or 25-mg capsules
Author(s): Allen Loyd V Jr
May/Jun 2002
Pg. 203
Ergoloid Mesylates 15-mg/mL and Selegiline HCl 6.25-mg/mL in PLO
Author(s): Allen Loyd V Jr
Jan/Feb 2012
Pg. 34-41
Compounded Pimobendan for Canine Chronic Degenerative Mitral Valve Disease and Pulmonary Hypertension
Author(s): Helms Scott R, Fox Samantha, Mixon William, Vail Jane
Jul/Aug 2002
Pg. 286-287
Medications Discontinued in the United States
Author(s): Ashworth Lisa D
Jan/Feb 2021
Pg. 43
Amlodipine Besylate 0.5-mg/mL to 10-mg/mL in SuspendIt Oral Suspension
Author(s): Allen Loyd V Jr
Jan/Feb 2021
Pg. 44
Clonidine 0.01-mg/mL in Oral Mix and Oral Mix SF Suspension
Author(s): Allen Loyd V Jr
Sep/Oct 2023
Pg. 420
Nitazoxanide 20-mg/mL Oral Suspension
Author(s): Allen Loyd V Jr
May/Jun 2018
Pg. 263
Erratum: Formulation: Lansoprazole 3-mg/mL Oral Suspension
Author(s):
Jan/Feb 2021
Pg. 47
Metronidazole 50-mg/mL in Oral Mix and Oral Mix SF Suspension
Author(s): Allen Loyd V Jr
Sep/Oct 2021
Pg. 415
Dapsone 2-mg/mL in Oral Mix or Oral Mix SF Suspension
Author(s): Allen Loyd V Jr
Sep/Oct 2021
Pg. 416
Dexamethasone 1-mg/mL in Oral Mix or Oral Mix SF Suspension
Author(s): Allen Loyd V Jr
Nov/Dec 2021
Pg. 503
Metoprolol Tartrate 10 mg/mL in SyrSpend SF pH4 Oral Suspension
Author(s): Allen Loyd V Jr
Nov/Dec 2021
Pg. 505
Pyridoxine Hydrochloride 25 mg/mL in Oral Mix and Oral Mix SF Suspension
Author(s): Allen Loyd V Jr